II-01 Thomas Dorlo Miltefosine treatment failure in visceral leishmaniasis in Nepal is associated with low drug exposure Wednesday 14:50-16:20 |
II-02 Anne Dubois Using Optimal Design Methods to Help the Design of a Paediatric Pharmacokinetic Study Wednesday 14:50-16:20 |
II-03 Cyrielle Dumont Influence of the ratio of the sample sizes between the two stages of an adaptive design: application for a population pharmacokinetic study in children Wednesday 14:50-16:20 |
II-04 Thomas Dumortier Using a model-based approach to address FDA’s midcycle review concerns by demonstrating the contribution of everolimus to the efficacy of its combination with low exposure tacrolimus in liver transplantation Wednesday 14:50-16:20 |
II-05 Mike Dunlavey Support in PML for Absorption Time Lag via Transit Compartments Wednesday 14:50-16:20 |
II-06 Charles Ernest Optimal design of a dichotomous Markov-chain mixed-effect sleep model Wednesday 14:50-16:20 |
II-07 Christine Falcoz PKPD Modeling of Imeglimin Phase IIa Monotherapy Studies in Type 2 Diabetes Mellitus (T2DM) Wednesday 14:50-16:20 |
II-08 Floris Fauchet Population pharmacokinetics of Zidovudine and its metabolite in HIV-1 infected children: Evaluation doses recommended Wednesday 14:50-16:20 |
II-09 Eric Fernandez drugCARD: a database of anti-cancer treatment regimens and drug combinations Wednesday 14:50-16:20 |
II-10 Martin Fink Animal Health Modeling & Simulation Society (AHM&S): A new society promoting model-based approaches for a better integration and understanding of quantitative pharmacology in Veterinary Sciences Wednesday 14:50-16:20 |
II-11 Sylvain Fouliard Semi-mechanistic population PKPD modelling of a surrogate biomarker Wednesday 14:50-16:20 |
II-12 Nicolas Frances A semi-physiologic mathematical model describing pharmacokinetic profile of an IgG monoclonal antibody mAbX after IV and SC administration in human FcRn transgenic mice. Wednesday 14:50-16:20 |
II-13 Chris Franklin : Introducing DDMoRe’s framework within an existing enterprise modelling and simulation environment. Wednesday 14:50-16:20 |
II-14 Ludivine Fronton A Novel PBPK Approach for mAbs and its Implications in the Interpretation of Classical Compartment Models Wednesday 14:50-16:20 |
II-15 Aline Fuchs Population pharmacokinetic study of gentamicin: a retrospective analysis in a large cohort of neonate patients Wednesday 14:50-16:20 |
II-16 Aurelie Gautier Pharmacokinetics of Canakinumab and pharmacodynamics of IL-1β binding in cryopyrin associated periodic fever, a step towards personalized medicine Wednesday 14:50-16:20 |
II-17 Ronette Gehring A dynamically integrative PKPD model to predict the efficacy of marbofloxacin treatment regimens for bovine Mannheimia hemolytica infection Wednesday 14:50-16:20 |
II-18 Peter Gennemark Incorporating model structure uncertainty in model-based drug discovery Wednesday 14:50-16:20 |
II-19 Eva Germovsek Age-Corrected Creatinine is a Significant Covariate for Gentamicin Clearance in Neonates Wednesday 14:50-16:20 |
II-20 TJ Carrothers Comparison of Analysis Methods for Population Exposure-Response in Thorough QT Studies Wednesday 14:50-16:20 |
II-21 Parviz Ghahramani Population PKPD Modeling of Milnacipran Effect on Blood Pressure and Heart Rate Over 24-Hour Period Using Ambulatory Blood Pressure Monitoring in Normotensive and Hypertensive Patients With Fibromyalgia Wednesday 14:50-16:20 |
II-22 Ekaterina Gibiansky Immunogenicity in PK of Monoclonal Antibodies: Detection and Unbiased Estimation of Model Parameters Wednesday 14:50-16:20 |
II-23 Leonid Gibiansky Monoclonal Antibody-Drug Conjugates (ADC): Simplification of Equations and Model-Independent Assessment of Deconjugation Rate Wednesday 14:50-16:20 |
II-24 Pascal Girard Tumor size model and survival analysis of cetuximab and various cytotoxics in patients treated for metastatic colorectal cancer Wednesday 14:50-16:20 |
II-25 Sophie Gisbert Is it possible to use the plasma and urine pharmacokinetics of a monoclonal antibody (mAb) as an early marker of efficacy in membranous nephropathy (MN)? Wednesday 14:50-16:20 |
II-26 Timothy Goggin Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies. Wednesday 14:50-16:20 |
II-27 Roberto Gomeni Implementing adaptive study design in clinical trials for psychiatric disorders using band-pass filtering approach Wednesday 14:50-16:20 |
II-28 José David Gómez-Mantilla Tailor-made dissolution profile comparisons using in vitro-in vivo correlation models. Wednesday 14:50-16:20 |
II-29 Ignacio Gonzalez-Garcia Simultaneous Modelling Of Fexofenadine In In Vitro Cell Culture And In Situ Experiments Wednesday 14:50-16:20 |
II-30 Sathej Gopalakrishnan Towards assessing therapy failure in HIV disease: estimating in vivo fitness characteristics of viral mutants by an integrated statistical-mechanistic approach Wednesday 14:50-16:20 |
II-31 Verena Gotta Simulation-based systematic review of imatinib population pharmacokinetics and PK-PD relationships in chronic myeloid leukemia (CML) patients Wednesday 14:50-16:20 |
II-32 Bruce Green Clinical Application of a K-PD Warfarin Model for Bayesian Dose Individualisation in Primary Care Wednesday 14:50-16:20 |
II-33 Zheng Guan The influence of variability in serum prednisolone pharmacokinetics on clinical outcome in children with nephrotic syndrome, based on salivary sampling combined with translational modeling and simulation approaches from healthy adult volunteers Wednesday 14:50-16:20 |
II-34 Monia Guidi Impacts of environmental, clinical and genetic factors on the response to vitamin D supplementation in HIV-positive patients Wednesday 14:50-16:20 |
II-35 Vanessa Guy-Viterbo Tacrolimus in pediatric liver recipients: population pharmacokinetic analysis during the first year post transplantation Wednesday 14:50-16:20 |
II-36 Chihiro Hasegawa Modeling & simulation of ONO-4641, a sphingosine 1-phosphate receptor modulator, to support dose selection with phase 1 data Wednesday 14:50-16:20 |
II-37 Michael Heathman The Application of Drug-Disease and Clinical Utility Models in the Design of an Adaptive Seamless Phase 2/3 Study Wednesday 14:50-16:20 |
II-38 Emilie Hénin Optimization of sorafenib dosing regimen using the concept of utility Wednesday 14:50-16:20 |
II-39 Eef Hoeben Prediction of Serotonin 2A Receptor (5-HT2AR) Occupancy in Man From Nonclinical Pharmacology Data. Exposure vs. 5-HT2AR Occupancy Modeling Used to Help Design a Positron Emission Tomography (PET) Study in Healthy Male Subjects. Wednesday 14:50-16:20 |
II-40 Taegon Hong Usefulness of Weibull-Type Absorption Model for the Population Pharmacokinetic Analysis of Pregabalin Wednesday 14:50-16:20 |
II-41 Andrew Hooker Platform for adaptive optimal design of nonlinear mixed effect models. Wednesday 14:50-16:20 |
II-42 Daniel Hovdal PKPD modelling of drug induced changes in thyroxine turnover in rat Wednesday 14:50-16:20 |
II-43 Hwi-yeol Yun Evaluation of FREM and FFEM including use of model linearization Wednesday 14:50-16:20 |
II-44 Ibrahim Ince Oral bioavailability of the CYP3A substrate midazolam across the human age range from preterm neonates to adults Wednesday 14:50-16:20 |
II-45 Lorenzo Ridolfi Predictive Modelling Environment - Infrastructure and functionality for pharmacometric activities in R&D Wednesday 14:50-16:20 |
II-46 Masoud Jamei Accounting for sex effect on QT prolongation by quinidine: A simulation study using PBPK linked with PD Wednesday 14:50-16:20 |
II-47 Alvaro Janda Application of optimal control methods to achieve multiple therapeutic objectives: Optimization of drug delivery in a mechanistic PK/PD system Wednesday 14:50-16:20 |
II-48 Nerea Jauregizar Pharmacokinetic/Pharmacodynamic modeling of time-kill curves for echinocandins against Candida. Wednesday 14:50-16:20 |
II-49 Roger Jelliffe Multiple Model Optimal Experimental Design for Pharmacokinetic Applications Wednesday 14:50-16:20 |
II-50 Sangil Jeon Population Pharmacokinetics of Piperacillin in Burn Patients Wednesday 14:50-16:20 |
II-51 Jeremie Guedj Modeling Early Viral Kinetics with Alisporivir: Interferon-free Treatment and SVR Predictions in HCV G2/3 patients Wednesday 14:50-16:20 |
II-52 Claire Johnston A population approach to investigating hepatic intrinsic clearance in old age: Pharmacokinetics of paracetamol and its metabolites Wednesday 14:50-16:20 |
II-53 Niclas Jonsson Population PKPD analysis of weekly pain scores after intravenously administered tanezumab, based on pooled Phase 3 data in patients with osteoarthritis of the knee or hip Wednesday 14:50-16:20 |
II-54 Marija Jovanovic Effect of Carbamazepine Daily Dose on Topiramate Clearance - Population Modelling Approach Wednesday 14:50-16:20 |
II-55 Rasmus Juul Kildemoes Pharmacokinetic modelling as a tool to assess transporter involvement in vigabatrin absorption Wednesday 14:50-16:20 |
II-56 Matts Kågedal A modelling approach allowing different nonspecific uptake in the reference region and regions of interest – Opening up the possibility to use white matter as a reference region in PET occupancy studies. Wednesday 14:50-16:20 |
II-57 Ana Novakovic Application of Item Response Theory to EDSS Modeling in Multiple Sclerosis Wednesday 14:50-16:20 |
II-58 Takayuki Katsube Pharmacokinetic/pharmacodynamic modeling and simulation for concentration-dependent bactericidal activity of a bicyclolide, modithromycin Wednesday 14:50-16:20 |
II-59 Irene-Ariadne Kechagia Population pharmacokinetic analysis of colistin after administration of inhaled colistin methanesulfonate. Wednesday 14:50-16:20 |
II-60 Ron Keizer cPirana: command-line user interface for NONMEM and PsN Wednesday 14:50-16:20 |
II-61 Frank Kloprogge Population pharmacokinetics and pharmacodynamics of lumefantrine in pregnant women with uncomplicated P. falciparum malaria. Wednesday 14:50-16:20 |
II-62 Gilbert Koch Solution and implementation of distributed lifespan models Wednesday 14:50-16:20 |
II-64 Julia Korell Gaining insight into red blood cell destruction mechanisms using a previously developed semi-mechanistic model Wednesday 14:50-16:20 |